Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia

Blood

Volumn 93, Issue 5, 1999, Pages 1732-1737

  Hallek, Michael ^a   Langenmayer, Irmgard ^b   Nerl, Christoph ^b   Knauf, Wolfgang ^b   Dietzfelbinger, Hermann ^b   Adorf, Dagmar ^b   Ostwald, Marianne ^b   Busch, Raymonde ^b   Kuhn Hallek, Ingrid ^b   Thiel, Eckhard ^b   Emmerich, Bertold ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; THYMIDINE KINASE;

ADULT; AGED; ARTICLE; CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; EARLY CANCER; ENZYME BLOOD LEVEL; FEMALE; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; LEUKOCYTE COUNT; LYMPHADENOPATHY; MALE; PRIORITY JOURNAL; PROGNOSIS; TUMOR GROWTH;

ADULT; AGED; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; THYMIDINE KINASE; TUMOR MARKERS, BIOLOGICAL;

EID: 0033106396     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, Vaugier G, Potron G, Colona P, Oberling F, Thomas M, Tchernia G, Jacquillat C, Boivin P, Lesty C, Duault MT, Monconduit M, Belabbes S, Gremy F: A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48:198, 1981
2. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS: Clinical staging of chronic lymphocytic leukemia. Blood 46:219, 1975
3. International Workshop on Chronic Lymphocytic Leukemia: Chronic lymphocytic leukemia: Recommendations for diagnosis, staging and response criteria. Ann Intern Med 110:236, 1989
4. Montserrat E, Hallek M: Current strategies for the treatment of CLL. Leuk Lymphoma 22:65, 1996 (suppl 2)
5. Rai KR, Rabinowe SN: Chronic lymphocytic leukemia, in Holland JF, Frei E III, Bast RC Jr, Kufe DW, Morton DL, Weichselbaum RR (eds): Cancer Medicine. Philadelphia, PA, Lea & Febiger, 1993, p 1971
6. Rozman C, Montserrat E: Chronic lymphocytic leukemia. N Engl J Med 333:1052, 1995
7. Foon KA, Rai KR, Gale RP: Chronic lymphocytic leukemia: New insights into biology and therapy. Ann Intern Med 113:525, 1990
8. Ellims PH, Eng Gan T, Medley G, van der Weyden MB: Prognostic relevance of thymidine kinase in adult non-Hodgkin's lymphoma. Blood 58:926, 1981
9. Gronowitz JS, Hagberg H, Källander CFR, Simonsson B: The use of serum deoxythymidine kinase as a prognostic marker, and in the monitoring of patients with non-Hodgkin's lymphoma. Br J Cancer 47:487, 1983
10. Hagberg H, Glimelius B, Gronowitz JS, Killander A, Källander CFR, Schröder T: Biochemical markers in non-Hodgkin's lymphoma stages III and IV and prognosis: A multivariate analysis. Scand J Haematol 33:59, 1984
11. Hallek M, Emmerich B, Strohmeyer S, Busch R, Reichle A, Senekowitsch R: Activity of serum thymidine kinase in non-Hodgkin lymphoma: Relationship to other prognostic factors. Klin Wochenschr 66:718, 1988
12. Källander CFR, Simonsson B, Hagberg H, Gronowitz JS: Serum deoxythymidine kinase gives prognostic information in chronic lymphocytic leukemia. Cancer 54:2450, 1984
13. Martinsson U, Glimelius B, Hagberg H, Sundstrom C: Prognostic relevance of serum-markers in relation to histopathology, stage and initial symptoms in advanced low-grade non-Hodgkin lymphomas. Eur J Haematol 40:289, 1988
14. Martinsson U, Glimelius B, Hagberg H, Sundstrom C: Primarily asymptomatic low-grade non-Hodgkin lymphomas: Prediction of symptom-free survival and total survival. Eur J Haematol 43:332, 1989
15. Hallek M, Wanders L, Ostwald M, Busch R, Senekowitsch R, Stern S, Schick H-D, Kuhn-Hallek I, Emmerich B: Serum β2-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. Leuk Lymphoma 22:439, 1996
16. Lennert K, Feller AC: Histopathologie der Non-Hodgkin-Lymphome (nach der aktualisierten Kiel-Klassifikation). Berlin, Germany, Springer-Verlag, 1990
17. Stansfeld AG, Diebold J, Kapanoi Y, Kelény G, Lennert K, Mioduszewska O, Noel H, Rilke F, Sundstrom C, van Unnik JAM, Wright DH: Updated Kiel classification for lymphomas. Lancet 1:292, 1988
18. Lennert K, Mohri N, Stein H, Kaiserling E: The histopathology of malignant lymphoma. Br J Haematol 31:193, 1975
19. Langenmayer I, Nerl C, Knauf W, Adolph S, Hallek M, Dietzfelbinger H, Maubach P, Ziegler-Heitbrock HWL, Thiel E, Emmerich B: Interferon alpha 2b in the treatment of early stage CLL with risk for progression. Results of a randomized multicenter study. Br J Haematol 94:362, 1996
20. Gronowitz JS, Hagberg H, Källander CFR, Simonsson B: Optimized assay for thymidine kinase and its application for the detection of antibodies against herpes simplex virus type 1- and 2-induced thymidine kinase. Infect Immun 29:425, 1980
21. Montserrat E, Sanchez BJ, Vinolas N, Rozman C: Lymphocyte doubling time in chronic lymphocytic leukaemia: Analysis of its prognostic significance. Br J Haematol 62:567, 1986
22. Molica S: Progression and survival studies in early chronic lymphocytic leukemia. Blood 78:895, 1991
23. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:157, 1958
24. LeBlanc M, Crowley J: Survival trees by goodness of split. J Am Stat Assoc 88:457, 1993
25. Cox D: Regression model and life-tables (with discussion). J R Stat Soc 34:187, 1972
26. Montserrat E, Vinolas N, Reverter JC, Rozman C: Natural history of chronic lymphocytic leukemia: On the progression and prognosis of early clinical stages. Nouv Rev Fr Hematol 30:359, 1988
27. French Cooperative Group on Chronic Lymphocytic Leukaemia: Natural history of stage A chronic lymphocytic leukaemia untreated patients. French Cooperative Group on Chronic Lymphocytic Leukaemia. Br J Haematol 76:45, 1990
28. Reichard P, Estborn B: Utilization of deoxyribosides in the synthesis of polynucleotides. J Biol Chem 188:839, 1951
29. Kit S: Viral-associated and induced enzymes. Pharmacol Therapeut 4:501, 1979
30. Bello LJ: Regulation of thymidine kinase synthesis in human cells. Exp Cell Res 89:263, 1974
31. Gronowitz JS, Källander CFR, Diderholm H, Hagberg H, Petterson U: Application of an in vitro assay for serum thymidine kinase: Results on viral disease and malignancies in humans. Int J Cancer 33:5, 1984
32. Källander CFR, Simonsson B, Gronowitz JS, Nilsson K: Serum deoxythymidine kinase correlates with peripheral lymphocyte thymidine uptake in chronic lymphocytic leukemia. Eur J Haematol 38:331, 1987
33. Lehtinen M, Wigren T, Lehtinen T, Kallioniemi OP, Aine R, Aaran RK, Ojala A: Correlation between serum tumor marker levels and tumor proliferation in small cell lung cancer. Tumour Biol 9:287, 1988
34. McKenna PG, O'Neill KL, Abram WP, Hannigan BM: Thymidine kinase activities in mononuclear leukocytes and serum from breast cancer patients. Br J Cancer 57:619, 1988
35. Hallek M, Wanders L, Strohmeyer S, Emmerich B: Thymidine kinase: A tumor marker with prognostic value for non-Hodgkin's lymphoma and a broad range of potential clinical applications. Ann Hematol 65:1, 1992
36. Knauf WU, Langenmayer I, Ehlers B, Hallek M, Zeigmeister B, Nerl C, Emmerich B, Thiel E: Serum levels of soluble CD23, but not of soluble CD25 are predictive for disease progression in early stage B-cell chronic lymphocytic leukemia. Leuk Lymphoma 27:523, 1997
37. Sarfati M, Chevret S, Chastang C, Biron G, Stryckmans P, Delespesse G, Binet J-L, Merle-Beral H, Bron D: Prognostic importance of serum soluble CD23 level in chronic lymphocytic leukemia. Blood 88:4259, 1996
38. Hallek M, Kuhn-Hallek I, Emmerich B: Prognostic factors in chronic lymphocytic leukemia. Leukemia 11:S4, 1997 (suppl 2)
39. Simonsson B, Wibell L, Nilsson K: β2-microglobulin in chronic lymphocytic leukemia. Scand J Haematol 24:174, 1980
40. Keating MJ, Lerner S, Kantarjian H, Freireich EJ, O'Brien S: The serum β2-microglobulin (β2m) level is more powerful than stage in predicting response and survival in chronic lymphocytic leukemia (CLL). Blood 86:606a, 1995 (suppl 1, abstr)